- Lenovo's Q1 Beats Expectations on China Strength
- Australia Jobs Jump, Stokes Talk of Rate Rise
- Cisco Wary on Recovery, but Earnings Beat Forecasts
- CEO Chambers: Cisco's Outlook Is Strong
- Jobless Data, Retail Sales to Challenge Stocks
- Berkshire Results May Show Buffett Still Has the Touch
- SEC's Schapiro: Ban on Flash Trading Will Take Time
- American Express Credit Card Defaults Fall
- Secrets Of The Super-Rich: How Are They Investing?
- Finally, A Useful Product
- Cisco Beats; But Will It Also Raise?
- Trade Commodities to Hedge Against Inflation: Strategist
- Stimulus Spending Fails to Follow Unemployment, Poverty
- Tough Times for Teen Apparel Retailers
- Schork Oil Outlook: 'We Should Look for an Artificial pop Next Month'
- Prepare For a 10-12% Inflation: Stock Picker
- Stock Picker: There's Room for More Market Growth
- When Bad News is Good; Cisco Prepares to Report
- PC maker Lenovo reports $16M loss amid weak demand
- NZ's jobless rate hits 6 percent, 10-year high
- Colombian businessman guilty in pyramid scandal
- Pest found in package had citrus disease
- Bobcat to cut 195 jobs in ND due to slow sales
- Fairpoint Communications posts 2Q loss of $17.8M
- Murphy Oil 2Q profit plunges on energy prices
- Automakers' shutdowns drive suppliers' 2Q losses
- 200,000 Black & Decker trimmers recalled
Clarification: Onyx Pharma story
Text Size 
WAYNE, N.J. - In a July 22 story about Onyx Pharmaceuticals Inc., The Associated Press described OSI Pharmaceuticals Inc. as a partner on the cancer drug Nexavar. The story should have specified that OSI is working with Onyx and others on a clinical trial of Nexavar, rather than as a marketing partner for the drug.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes